BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pulmatrix Demonstrates Superiority of in Delivering An Effective Multi-Drug Inhaled Dose Compared to Conventional Formulation


10/31/2011 6:38:46 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that it has demonstrated that iSPERSE™, its inhaled drug platform, shows superiority in delivering an effective therapeutic dose of the active ingredients in Advair®, salmeterol and fluticasone, compared to conventional lactose blend Advair. These data from in vitro studies show the potential of iSPERSE, a proprietary cationic salt formulation inhaled as a dry powder, to efficiently deliver consistent doses, which can have relevance to patients having lower or impaired lung function. Based on these and other data, Pulmatrix is now advancing a number of proprietary iSPERSE drug formulation candidates including small molecules, combinations and biologics in a variety of therapeutic areas, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and non-CF bronchiectasis, as well as pursuing partnerships for iSPERSE.

Read at BioSpace.com

Pulmatrix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES